FDA Approves First Protac Drug for Breast Cancer — SkimNews
SkimNews Take
By outsourcing protein elimination to the cell's own degradation machinery, protacs sidestep the long-standing requirement that drugs must bind functional sites—effectively converting any sufficiently exposed protein surface into a therapeutic target.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Vepdegestrant, the first protac drug, was approved by the US Food and Drug Administration in May after trials showed patients with advanced breast cancer that had spread survived more than twice as long as those given a conventional drug.
- Protacs attach a ubiquitin "recycle me" label to a disease-causing protein, marking it for destruction by the cell's proteasome; because a single protac molecule can tag tens to hundreds of target proteins, they sidestep the one-to-one binding limitation of conventional drugs.
- Unlike small-molecule drugs and antibodies, protacs do not need to bind a protein's active site, allowing them to attack targets long classified as "undruggable" because no such binding pocket exists.
- The protac concept originated with Craig Crews and Raymond Deshaies at a 1998 conference; Crews founded Arvinas in 2013 to commercialize them as "large small-molecules" small enough to behave like pills.
- Crews has also developed riptacs, which link a protein abundant in cancer cells to one essential for cell survival, killing malignant cells; Johnson & Johnson acquired the technology after a successful initial prostate cancer trial.
- Around 100 companies are working on targeted protein degradation, with roughly 80 trials under way, according to Crews, who expects the approval to accelerate the field.
Why it matters: For patients with advanced breast cancer resistant to existing hormone therapies, vepdegestrant more than doubles survival time in trials—a tangible clinical gain, not a lab curiosity. Beyond breast cancer, protacs can in principle hit proteins long called "undruggable," and the field already has around 100 companies and 80 trials pursuing the next targets.
Ask SkimNews
